Summary
- Profile Type
- Business Offer
- POD Reference
- BOGB20250417020
- Term of Validity
- 17 April 2025 - 17 April 2026
- Company's Country
- United Kingdom
- Type of partnership
- Commercial agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
-
The expertise of the UK business spans across standard antiviral testing, customized assay development, and tailored research solutions, supporting the discovery and evaluation of novel antiviral compounds, vaccines, and therapeutics.
With a strong focus on scientific excellence and innovation, the UK business offers high-quality, data-driven insights to advance virology research. - Full Description
-
The UK company offers a comprehensive suite of virology research services, including:
• Standardized antiviral testing against a wide range of human viruses.
• Custom assay development, tailored to specific research needs.
• Mode-of-action studies, cytotoxicity assessments, and resistance profiling.
• Specialized high-containment research (CL3), allowing work with high-risk pathogens.
They are seeking commercial partners in Europe in pharmaceutical, biotechnology, and healthcare sectors for contract research work to support preclinical antiviral drug and vaccine development .
Through strategic international partnerships, the CRO works towards:
• Accelerating the development of novel antiviral treatments and innovative virology solutions.
• Expands access to cutting-edge virology expertise for global partners.
• Fosters long-term collaborations that drive impactful scientific advancements.
They are keen to engage with European partners interested in leveraging their expertise for mutual growth and innovation.
Operating from state-of-the-art Containment Level 2 and 3 laboratories in the UK, the CRO partner with businesses worldwide across pharmaceutical, biotechnology, and healthcare industries - Advantages and Innovations
-
The UK CRO differentiate themselves through scientific excellence, flexibility, and a client-focused approach. Their cutting-edge Containment Level 2 and 3 (CL2/CL3) facilities and specialized expertise allow them to deliver high-quality, tailored virology research solutions that set us apart from competitors.
Advanced High-Containment Capabilities – Unlike many CROs, the UK company offers specialized CL3 research services, enabling work with high-risk pathogens and expanding the scope of antiviral and vaccine development.
Custom, Client-Centric Approach – They provide bespoke research solutions tailored to each client's specific needs, unlike larger CROs that often rely on standardized protocols.
Rapid Turnaround & Agile R&D – Their team’s scientific expertise and streamlined workflows ensure fast, reliable results, reducing development timelines for their partners.
Industry & Academic Collaborations – they actively partner with biotech, pharma, and research institutions, fostering innovation and cross-disciplinary advancements in virology.
Comprehensive Virology Expertise – From antiviral efficacy testing to mechanism-of-action studies and resistance profiling, they offer a full suite of virology research services, making us a one-stop solution for preclinical antiviral development - Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 17: Partnerships to achieve the Goal
- Goal 12: Responsible Consumption and Production
- Goal 3: Good Health and Well-being
- Goal 1: No Poverty
- Goal 10: Reduced Inequality
- IPR status
- Secret know-how
Partner Sought
- Expected Role of a Partner
-
The UK company is seeking collaborative partners from the pharmaceutical, biotechnology, and healthcare industries, as well as academic and research institutions, to advance virology research and antiviral development.
They are seeking collaborators to work on innovative research projects including co-development of novel technologies to enhance antiviral research. - Type and Size of Partner
- R&D Institution
- SME 50 - 249
- SME <=10
- Type of partnership
- Commercial agreement
Dissemination
- Market keywords
- 05001002 - In-vitro diagnostics
- 05006 - Anatomy, Pathology, Immunology, Physiology
- 05001007 - Other diagnostic
- 05001001 - Diagnostic services
- 05001005 - Molecular diagnosis
- Sector Groups Involved
- Health
- Targeted countries
- All countries